CTOs on the Move


 
ONI is a pioneer of next generation super-resolution microscopy, making this advanced technology accessible to new generations of researchers. The Nanoimager, the world`s first benchtop sized super-resolution microscope, delivers a step change in usability and precision. The microscope offers easy access to a range of super-resolution techniques including dSTORM and PALM, as well as smFRET, single-particle tracking and confocal. The company`s achievements have been recognised by FastTrack100 who named ONI on their 2018 list of 10 Disruptors to Watch and ONI won Best Business Start-up at the 2018 IOP Awards. More and more life science researchers and pharma companies are ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.oni.bio
  • 9310 Athena Circle Suite 220
    San Diego, CA USA 92037
  • Phone: n/a

Executives

Name Title Contact Details
Tyler Ralston
Chief Technology Officer Profile

Similar Companies

Advanced Diagnostic Group

Advanced Diagnostic Group is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

STEMCELL Technologies

STEMCELL Technologies is a biotechnology company that develops specialty cell culture media and cell separation products to support research in the fields of immunology, hematology, neuroscience, mesenchymal cell, stem cell and epithelial cell biology. We also provide instruments, cytokines, antibodies, training courses, proficiency testing and contract assay services. Driven by science and a passion for quality, STEMCELL delivers over 2500 products to more than 80 countries worldwide. STEMCELL Technologies provides consistent, unfailing quality and one-on-one assistance to help you succeed. We do this because we love science as much as you do.

New Jersey Precision Technology

New Jersey Precision Technology is a Mountainside, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biolife Plasma Services

Biolife Plasma Services is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aruvant

Aruvant`s mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD). Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment for SCD. Preliminary clinical data from the ongoing Phase 1/2 study demonstrated durable efficacy in reducing the negative impacts of SCD. We are preparing for the launch of our pivotal clinical trial in SCD. We continue to look for new people to add to our talented team.